Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 15/20 | 0.83 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151554 | 1.00 | SRD5A2 (0.83) | SRD5A2SRD5A1 | |
| SCHEMBL8994170 | 0.91 | SRD5A2 (0.69) | SRD5A2SRD5A1 | |
| SCHEMBL17268601 | 0.91 | SRD5A2 (0.77) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL23833504 | 0.91 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL5444493 | 0.91 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL61222 | 0.91 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| Epristeride SCHEMBL16115063 | 0.91 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| SCHEMBL9391101 | 0.90 | SRD5A2 (0.68) | SRD5A2SRD5A1 | |
| SCHEMBL9396243 | 0.90 | SRD5A2 (0.68) | SRD5A2SRD5A1 | |
| SCHEMBL9113743 | 0.90 | SRD5A2 (0.68) | SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0289327-B1 | STEROID 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-18 | — | — | EP | claimed |
| EP-0289327-A2 | Steroid 5-alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-11-02 | — | — | EP | claimed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0289327-B1 | STEROID 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-18 | — | — | EP | disclosed |
| US-5017568-A | Enzyme inhibitors, carboxylation | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0289327-A2 | Steroid 5-alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-11-02 | — | — | EP | disclosed |